Abstract

PERSPECTIVES OF SOTAGLIFLOZIN THE FIRST DUAL SGLT PERSPECTIVES OF SOTAGLIFLOZIN THE FIRST DUAL SGLT PERSPECTIVES OF SOTAGLIFLOZIN THE FIRST DUAL SGLT PERSPECTIVES OF SOTAGLIFLOZIN THE FIRST DUAL SGLT PERSPECTIVES OF SOTAGLIFLOZIN THE FIRST DUAL SGLT PERSP

*Dr. Spoorthy Mithra and S. Navyasree Anusha

ABSTRACT

Context: Heart failure (HF) is a chronic disorder that decreases heart function and causes a person to be less tolerant to exercise, have a lower quality of life, and prone to death. Novel therapeutic strategies are still needed despite improvements in HF management. Sotagliflozin is a promising medication for the treatment of HF, which is a dual sodium-glucose cotransporter 1 as well as 2 (SGLT1 and SGLT2) inhibitors. Sotagliflozin has been shown to be effective in lowering the risk of HF hospitalization and heart attack in patients with HF with either type 2 diabetic mellitus (T2DM) and chronic kidney disease (CKD), according to numerous randomized trials, including the most recent SOLOIST-WHF or SCORED trials.

Keywords: .